Navigation Links
Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/11/2008

SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its lead candidate, new HspE7 (HspE7 + Poly-ICLC, a toll-like receptor-3, or TLR3 agonist), in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. New HspE7 is an investigational therapeutic vaccine targeting human papillomavirus (HPV)-related diseases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"Conclusion of enrollment in this study is a significant milestone for Nventa," said Gregory M. McKee, President and Chief Executive Officer at Nventa. "We have spent considerable time analyzing the need for a fifth cohort in this study, and have determined that the fourth cohort dose level is likely optimal for future clinical trials. Following completion of this Phase 1 study, we anticipate launching a comprehensive Phase 2 program studying the safety and efficacy of new HspE7 in patients with CIN."

When complete, the Phase 1 trial will have dosed four cohorts totaling seventeen patients with a fixed dose of 500 mcg of HspE7 and either 50, 500, 1,000 or 2,000 mcg of the adjuvant, Poly-ICLC. In addition to safety data, immunological data are being collected pre-treatment, following each dose of new HspE7, and at the end of the study from all patients, which could provide an early indication of potential activity of new HspE7. All patients are also being typed for class I and II human leukocyte antigen (HLA) subtypes, and are being evaluated for cytokine responses, anti-HspE7 antibodies and cellular (T-cell) immunology.

Affiliations and investigators in this trial currently have included the Montefiore Medical Center
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
5. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
8. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
9. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
10. Northwestern Memorial Transplant Program Initiates New Study
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- SeraCare Life Sciences, a leading partner to global ... AACC Annual Meeting today that it has signed ... biotechnology company that develops, markets and sells preanalytic ... ViveST™ allow sample collection, transport and storage in ... of the agreement, the two firms will jointly ...
(Date:7/27/2015)... July 27, 2015  The fairness of the proposed ... St. Jude Medical ("St. Jude") is the subject of ... shareholder rights law firm.  The investigation is focusing on ... law by the Board of Directors of THOR for ... July 22, 2015, the Company announced it had reached a ...
(Date:7/27/2015)... , July 20, 2015 ... has announced the addition of the "Cardiometabolic ... Afrezza,s discounted pricing is in line ... is critical to the product,s commercial appeal. However, ... prevent Afrezza from gaining a sizeable share of ...
Breaking Medicine Technology:SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 2SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 3WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3
... Motion Therapeutics, Inc. http://www.motiontherapeutics.com , the leading provider ... today announced that researchers at Samuel Merritt University and ... to study the effects of wearing a strategically weighted ... MS. This grant comes after the ...
... Argon Medical Devices, Inc. announced today that it ... LP ("Rex Medical") for exclusive global rights to market and ... device used in the prevention of Pulmonary Embolism (PE). ... to our product portfolio. This proven technology has rapidly become ...
Cached Medicine Technology:The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 3
(Date:7/28/2015)... ... July 28, 2015 , ... ... that Schneider Electric has completed its upgrade and expansion of its ... with more than 170,000 employees in 134 countries supplying a wide range of ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... biologics and biologic-device combination products for the treatment of bone disorders and conditions ... Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". The ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new Taiwanese study suggests ... are in the general population. Surviving Mesothelioma has just posted an article detailing ... at Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the health ...
(Date:7/28/2015)... MA (PRWEB) , ... July 28, 2015 , ... Women ... cancer. One reason is that cancer, heart attack, and stroke are treatable, but there ... thing individuals can do is to take part in a clinical trial, reports the ...
(Date:7/28/2015)... ... July 28, 2015 , ... Every summer, the public is reminded ... caution when lighting fireworks in their own neighborhoods. Unfortunately, according to a recent report ... 3, 2015 USA Today article " Eye Injuries Caused by Fireworks Doubled in Last ...
Breaking Medicine News(10 mins):Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3
... (Jan. 17, 2008) Twenty research projects have been ... at the Argonne Leadership Computing Facility (ALCF) at Argonne ... competitively selected group of 55 scientific projects announced Thursday ... awards are made through the 2008 Innovative and Novel ...
... diagnostic tool to detect surface cancers quickly and ... calculate body composition has been developed by a ... from QUTs School of Physical and Chemical Sciences ... spectroscopy to diagnose cervical and skin cancers. , ...
... stroke and even death, study finds , , FRIDAY, ... to aspirin are four times more likely to suffer a ... says. , People who are aspirin-resistant have platelets -- the ... in the same way as platelets in people who respond ...
... Jan. 18 Cardiac Science,Corporation (Nasdaq: ... cardiac diagnosis,resuscitation, rehabilitation, and informatics products, announced ... its first responder units with,425 Powerheart(R) G3 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO ), "Like first ...
... Farm Safety 4 Just Kids Founder, Adams, Reaches Finals of 6th Annual Volvo ... Celebrity Judges Will Select and Unveil Top Four Winners March 19 at Volvo,for life ... ... Life, IRVINE, Calif., Jan. 18 For the past ...
... Jan. 18 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: ... reduction in its,overall headcount affecting approximately 115 people ... U.S. subsidiaries, including members,of its management team., ... undertaken by the,Company as part of its strategic ...
Cached Medicine News:Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 2Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 3Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 4Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 5Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 6Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 7Health News:Cardiac Science Completes Deployment of AEDs With Los Angeles County Fire Department 2Health News:Cardiac Science Completes Deployment of AEDs With Los Angeles County Fire Department 3Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 2Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 3Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 4Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 5Health News:QLT reduces workforce as first step in its strategic restructure 2Health News:QLT reduces workforce as first step in its strategic restructure 3
... care challenge., ,The S/5 Critical Care Monitor ... solution for the varying needs of critical care. ... of parameter module options, display and mounting options, ... optimize the bedside set-up to help meet your ...
... connectivity, ,The wireless functionality is an ... that makes it possible to connect S/5 ... S/5 Central Station via Wireless LAN technology., ... of providing continuous centralized surveillance within the ...
... day surgery and post anesthesia care in one ... is a high performance monitor designed for the ... and induction rooms. It offers the flexibility of ... advanced airway gas monitoring. When paired with the ...
Anesthetists Precordial Kit incudes one set of 4 chromed plated chest pieces, a reusable monoscope of your choice, and 20 precordial adhesive discs....
Medicine Products: